Related Experiment Videos
Guidelines for the use of antiretroviral agents in pediatric HIV infection--HRSA. Request for comments
Insights
New guidelines offer crucial insights into using antiretroviral therapy for pediatric Human Immunodeficiency Virus (HIV) infection. These recommendations address unique challenges in treating children and adolescents with HIV.
Area of Science:
- Pediatric Infectious Diseases
- Antiretroviral Therapy
- Public Health Guidelines
Background:
- Human Immunodeficiency Virus (HIV) infection presents unique challenges in pediatric populations.
- Antiretroviral therapy principles are similar across age groups, but pediatric considerations differ significantly.
- Specialized guidelines are needed for the effective management of HIV in infants, children, and adolescents.
Purpose of the Study:
- To provide updated guidelines for the use of antiretroviral agents in pediatric HIV infection.
- To address pediatric-specific issues in antiretroviral treatment and management.
- To offer guidance to healthcare providers caring for HIV-infected children and adolescents.
Main Methods:
- Development of guidelines by a multidisciplinary panel including specialists, family members, and government representatives.
- Convened meeting by the National Pediatric and Family HIV Resource Center (NPHRC) and HRSA.
- Review of existing knowledge and specific pediatric considerations in HIV treatment.
Main Results:
- Identified unique pediatric considerations including perinatal infection, in utero medication exposure, and developmental differences.
- Highlighted age-related variations in diagnostic evaluation, immunologic markers (e.g., CD4+ counts), and pharmacokinetics.
- Addressed clinical manifestations and adherence challenges specific to pediatric HIV infection.
Conclusions:
- The developed guidelines address critical pediatric-specific issues in antiretroviral treatment.
- These guidelines aim to improve the care and management of HIV-infected infants, children, and adolescents.
- The document serves as a vital resource for physicians managing pediatric HIV cases.
Abstract:
The Health Resources and Services Administration (HRSA) is requesting comments from all interested parties on the following document: "Guidelines for Use of Antiretroviral Agents in Pediatric HIV Infection". The document was developed by specialists in the care of HIV-infected infants, children and adolescents, family members of HIV-infected children, and governmental agency representatives at a meeting on July 9 and 10, 1997, convened by the National Pediatric and Family HIV Resource Center (NPHRC) and HRSA. While the pathogenesis of HIV infection and the general virologic and immunologic principles underlying the use of antiretroviral therapy are similar for all HIV infected individuals, there are therapeutic and management considerations that are unique to HIV infected infants, children and adolescents. These include acquisition of infection through perinatal exposure for many infected children; in utero exposure to zidovudine (ZDV) and other antiretroviral medications in many perinatally-infected children; differences in diagnostic evaluation in perinatal infection; differences in immunologic markers (e.g. CD4+ lymphocyte count) in young children; changes in pharmacokinetic parameters with age due to the continuing development and maturation of organ systems involved in drug metabolism and clearance; differences in the clinical and virologic manifestations of perinatal HIV infection secondary to the occurrence of primary infection in a still-developing, immunologically naive individual; and special considerations related to treatment adherence in children and adolescents. This document addresses the pediatric-specific issues related to antiretroviral treatment and provides general guidelines to physicians caring for infected children and adolescents.